TY  - GEN

T1  - 33781 Sustained and durable response up to 24 weeks after last dose observed in a phase 2a study (NCT03754309) of amlitelimab (KY1005, SAR445229) a novel nondepleting anti-OX40Ligand (OX40L) mAb in patients with moderate to severe atopic dermatitis (AD)

PY  - 2022/09/01

AU  - Weidinger S

AU  - Bieber T

AU  - Cork M

AU  - Reich A

AU  - Brennan N

AU  - Quaratino S

AU  - Wilson R

AU  - Porter-Brown B

ED  - 

Y2  - 2024/12/22

ER  -